Robert Bosch Krankenhaus GmbH — Clinical Trial Site

50 Registered trials

21 Currently recruiting

Organisation

Robert Bosch Krankenhaus GmbH

Location

Stuttgart, Germany

Identifier

ORG-100017382

Address

Auerbachstrasse 110, Bad Cannstatt, 70376, Germany

Departments

-
#2123 Abteilung für Allgemeine Innere Medizin und Nephrologie
#3410: Abteilung fuer Allgemeine Innere Medizin und Nephrologie
1112:Klinik fuer Allgemeine Innere Medizin und Nephrologie
2214: Kardiologie und Angiologie
2329: Abteilung fuer Kardiologie und Angiologie
5223: Abteilung für Allgemeine Innere Medizin und Nephrologie
Abteilung fuer Pneumologische Onkologie
Abteilung für Hämatologie, Onkologie und Palliativmedizin
Abteilung für Hämatologie, Onkologie und Palliativmedizi
Abteilung für Hämatologie, Onkologie und Palliativmedizin
Abteilung für Kardiologie und Angiologie
Abteilung für Pneumologie und Beatmungsmedizin RBK Lungenzentrum Stuttgart
Abteilung für Pneumologische Onkologie
Abteilung Pneumologie und Beatmungsmedizin
Department of Anesthesiology and Intensive Care Medicine
Department of Hematology, Oncology and Palliative Care
Dpt. of Pneumology and Critical Care Medicine
Gastroenterologie, Hepatologie u. Endokrinologie kooperierend mit der Molekularen Onkologie
Gastroenterologie, Hepatologie und Endokrinologie
General Internal Medicine and Nephrology
general internal medicisne and nephrology
Gynäkologie und Geburtshilfe
Haemotology, Oncology and Palliative Medicine
Hämatologie, Onkologie und Palliativmedizin
Hämatologie, Onkologie und Palliativmedizin, RBK Lungenzentrum Stuttgart
Hämatologie/Onkologie
Hemato-Oncology
Hematology
Hematology/Oncology
Innere Medizin III - Haematologie und Onkologie
Klinik Schillerhöhe
Klinik Schillerhöhe Abteilung für Pneumologische Onkologie
Klinik Schillerhöhe, Pneumologische Onkologie
Molekulare Onkologie und Pneumologische Onkologie
N/A
Nephrology
Oncology
R.B.Gesellschaft für medizinische Forschung Klinik für Onkologie, Haematologie und Palliativmedizin
Robert-Bosch-Krankenhaus Stuttgart - Behandlungsexzellenz Bosch Health Campus
Robert-Bosch-Krankenhaus Stuttgart, Abteilung Hämatologie, Onkologie, Studieneinheit ZIM2

Clinical trials at this site (50)

Search interface

ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 The medical condition we are investigating is type 1 AM 5 2024-08-01
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended

2022-502669-14-00 Small cell lung cancer (SCLC) 5 2023-12-18
A Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephr… Ended

2022-502102-32-00 Primary Immunoglobulin A (IgA) Nephropathy 5 2023-11-16
A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (… Ended

2024-515902-15-00 Male and female adult patients with locally advanced or 4 2022-01-18
A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with prim… Ended

2023-508690-92-00 IgA Nephropathy 11 2021-09-20
A Phase II clinical trial comparing the efficacy of RO7198457 versus watchful waiting in patients with ctDNA positive, resected Stage II (hi… Ended

2023-509516-28-00 Stage II/Stage III rectal cancer or Stage II (high risk 4 2021-02-22
A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients … Ended

2023-506576-27-00 EGFR-mutated locally advanced or metastatic Non Small C 5 2020-09-30
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Ended

2024-518077-34-00 locally advanced rectal cancer 5 2020-09-30
Comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AML Ended

2024-515375-35-00 Untreated patients with higher risk MDS and oligoblasti 4 2019-08-26
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll… Ended

2023-509602-29-00 Patients with Limited Stage Small-Cell Lung Cancer (LS- 5 2019-02-11
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
Phase 2b study to investigate the safety and efficacy of TIN816 in SA-AKI Ended

2023-505903-22-00 Sepsis associated acute kidney injury 4 2024-07-02
ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients with Chronic Kidney Disease (CKD) from Cardiac Surgery Associated Acute Kidney … Ended

2022-501802-36-00 Prevention of cardiac surgery associated acute kidney i 5 2023-06-16
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af… Ended

2024-510590-14-00 multiple myeloma 5 2023-03-03
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended

2024-511263-28-00 Hypercholesterolemia 6 2022-04-08
GRAPPA Ended

2023-510441-24-00 Graft Vs Host Disease Peripheral Blood Stem Cell Transp 5 2022-01-28
Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended

2024-511067-29-00 IgA Nephropathy 5 2021-01-25
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended

2023-505035-12-00 RET fusion−positive, metastatic Non-Small Cell Lung Can 5 2020-06-12
Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (TUD-RELAX1-070) Ended

2024-514018-12-00 female and male adult patients with acute myeloid leuke 9 2020-04-06
A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended

2022-502886-71-00 Previously Untreated Locally Advanced Non-small Cell Lu 5 2019-11-20
MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse Ended

2024-513956-14-00 Acute myeloid leukemia 4 2019-09-16
Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended

2023-505494-32-00 Focal segmental glomerulosclerosis (FSGS) 5 2018-10-15
A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV … Ended

2023-508757-75-00 Stage IV Non-Small Cell Lung Cancer (NSCLC) 5 2017-09-18
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15